ReviewFrontiers in pharmacology2021
Targeted Therapeutic Strategies in the Battle Against Pathogenic Bacteria.
Review in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 62 citations in OpenAlex.
- Virobiome-mediated regulation of microbiota-gut-brain axis signaling and neuroimmune homeostasis.Cell communication and signaling : CCS · 2026Review
- The maternal and infant gut microbiome: implications for pregnancy outcomes, immune development, and health in the first 1000 days.Journal of translational medicine · 2026Review
- Antibody-Antibiotic Conjugates: Mechanisms, Clinical Progress, and Next-Generation Strategies Against Multidrug-Resistant Bacterial Infections.MicrobiologyOpen · 2026Review
- Decoding the Gut-Brain Axis in Alzheimer's Disease: Emerging Perspectives.CNS & neurological disorders drug targets · 2026Review
- Safe Meat, Smart Science: Biotechnology's Role in Antibiotic Residue Removal.Antibiotics (Basel, Switzerland) · 2025Review
- Engineered phage-silver nanoparticle complexes as a new tool for targeted therapies.Scientific reports · 2025Article
- Synthetic Biology-Based Engineering Living Therapeutics for Antimicrobial Application.Exploration (Beijing, China) · 2025Article
- Metformin Enhances Doxycycline Efficacy AgainstMicroorganisms · 2025Article
- Green Solid-State Synthesis of Antibacterial Binary Organic Material: Crystal Growth, Physicochemical Properties, Thermal Study, Antibacterial Activity, and Hirshfeld Surface Analysis.International journal of molecular sciences · 2025Article
- Inhibition of pneumococcal growth and biofilm formation by human isolates ofApplied and environmental microbiology · 2025Article
- A Precision Medicine Model for Targeted Antibiotic Therapy in Urinary Tract Infections: A Valuable Tool to Reduce Hospitalization Stay and the Time to Switch to Oral Treatment.Antibiotics (Basel, Switzerland) · 2025Article
- Therapeutic and protective approaches to combatFrontiers in pharmacology · 2025Review
- Niche-specific metabolic phenotypes can be used to identify antimicrobial targets in pathogens.PLoS biology · 2024Article
- Article
- Diagnostic and Therapeutic Challenge Caused byPathogens (Basel, Switzerland) · 2024Review
- Role of the microbiota in response to and recovery from cancer therapy.Nature reviews. Immunology · 2024Review
- Non-odontogenic maxillofacial infections - a 17-years retrospective cohort study.Oral and maxillofacial surgery · 2024Article
- Anti-Acinetobacter Baumannii single-chain variable fragments provide therapeutic efficacy in an immunocompromised mouse pneumonia model.BMC microbiology · 2024Article
- Isolation and characterization of a VHH targeting the Acinetobacter baumannii cell surface protein CsuA/B.Applied microbiology and biotechnology · 2023Article
- Pathogen-Targeted Clinical Development to Address Unmet Medical Need: Design, Safety, and Efficacy of the ATTACK Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence and rapid spread of antibiotic resistance in pathogenic bacteria constitute a global threat for public health. Despite ongoing efforts to confront this crisis, the pace of finding new potent antimicrobials is far slower than the evolution of drug resistance. The abuse of broad-spectrum antibiotics not only accelerates the formation of resistance but also imposes a burden on the intestinal microbiota, which acts a critical role in human homeostasis. As such, innovative therapeutic strategies with precision are pressingly warranted and highly anticipated. Recently, target therapies have achieved some breakthroughs by the aid of modern technology. In this review, we provide an insightful illustration of current and future medical targeted strategies, including narrow-spectrum agents, engineered probiotics, nanotechnology, phage therapy, and CRISPR-Cas9 technology. We discuss the recent advances and potential hurdles of these strategies. Meanwhile, the possibilities to mitigate the spread of resistance in these approaches are also mentioned. Altogether, a better understanding of the advantages, disadvantages, and mechanisms of action of these targeted therapies will be conducive to broadening our horizons and optimizing the existing antibacterial approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.